Exchange: NASDAQ·Updated 07:34 PM EDT
Latest Earnings Results: Q2 '26

Reported: Aug 06

Estimated EPS

$0.08

Reported EPS

$0.43

Surprise

+446.19%

Estimated Rev

$97.63M

Reported Rev

$108.02M

Surprise

+10.64%

$RGNX Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $0.43 up 131.16% YoY • Reported revenue of $108.02M up 405.73% YoY • REGENXBIO expects its balance in cash, cash equivalents, and marketable securities as of June 30, 2026, plus July 2026 proceeds, are sufficient to fund operations for REGENXBIO into Q4 2027.

Generated by Stocktwits using AI and company-reported earnings data for Q2 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.

Historical Earnings

Quarterly

Annual

EPS

Revenue

Fiscal PeriodEstimatedReportedSurpriseResult
Q3 '26
-$1.21
--
--
N/A
Q2 '26
$0.08
$0.43
446.19%
BEAT
Q1 '26
-$1.34
-$1.72
-28.65%
MISSED
Q4 '25
-$0.88
-$1.30
-48.52%
MISSED
Q3 '25
-$1.30
-$1.20
7.81%
BEAT

Advertisement|Remove ads.